News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Courtagen Life Sciences, Inc. Announces Collaboration With Raptor Pharmaceutical Inc. (RPTP) For Leigh Syndrome And Other Mitochondrial Disorders



3/25/2014 8:32:33 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences announced today an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing in the clinical trial for RP103 as a potential treatment for Leigh syndrome and other mitochondrial disorders. Leigh syndrome is a severe neurological disorder caused by genetic defects in mitochondrial or nuclear DNA affecting respiratory chain function that typically results in death within the first decade of life.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES